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Abstract The objective was to ret-
rospectively characterise the effi-
cacy of memantine as preventive
therapy in a series of patients with
frequent migraine. Patients in a
university headache clinic com-
pleted a survey regarding their
experience with memantine, and
medical records were reviewed. All
patients who received memantine
as preventive therapy for migraine
over a 15-month period were
mailed surveys and consent forms
for record review. Patients were
treated with memantine beginning
at a dose of 5 mg/day, increasing if
needed by 5 mg/week up to 10 mg
twice a day. The majority of
patients (36 out of 54) treated with
memantine for at least 2 months
reported a significant reduction in
estimated headache frequency, and
improved function. Side effects
were uncommon and generally
mild. This limited retrospective
case review suggests that meman-
tine may be an effective preventive
therapy for patients with frequent
migraine. A prospective trial is
warranted. 
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Introduction
Despite the existence of multiple well established migraine
preventive therapies, there is a significant proportion of
migraine patients for whom currently available therapies are
either ineffective or poorly tolerated. Migraine is increasingly
viewed as an episodic disorder of brain excitability. Signalling
by glutamate, the primary excitatory neurotransmitter in the
central nervous system, is therefore an appealing target for
migraine therapy [1]. NMDA receptor antagonists are known
to inhibit cortical spreading depression (CSD), which is
believed to be a fundamental mechanism of migraine.
Memantine is a low-affinity, open channel blocker of NMDA
receptor channels that is FDA approved in the United States
for the treatment of Alzheimer’s disease [2, 3]. We have used
memantine to treat patients with headache, the majority of
whom had failed standard acute and preventive therapy. This
report describes the initial experience of our patients with
memantine as a treatment for prevention of migraine.
Methods
Patients were independently evaluated and treated by one of three dif-
ferent neurologists (AC, CF or KCB). A diagnosis of migraine was
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made based on ICDH-II criteria. A significant number had addition-
al diagnoses of chronic migraine or medication overuse headache
that were not considered independently of the migraine diagnosis.
Patients were treated with memantine beginning at a dose of 5 mg
once a day, increasing by 5 mg/week to as much as 10 mg twice a
day. Patients were maintained at the lowest dose at which they were
satisfied with the reduction in headache frequency. Most patients
were provided medication samples to initiate therapy; some patients
whose health insurance covered the cost of the medication were writ-
ten a prescription to obtain the medication at a pharmacy. UCLA IRB
approval was obtained to perform a retrospective case review. All
migraine patients who had received memantine for at least 2 months
were mailed a one-page survey, as well as a consent form to autho-
rise review of medical records and anonymous reporting of their
experience. Most patients based their responses on a headache diary,
but these were not required for inclusion in the case review;
headache frequencies are therefore estimates that may be significant-
ly confounded by recall bias.
Results
Surveys and consents were mailed to 71 migraine patients
who had been treated with memantine – of these 60 respond-
ed. Patient ages ranged from 14 to 78 years (mean age 49,
median age 52); 49 were females and 11 were males. Twenty
had migraine with aura and 40 had migraine without aura
according to ICDH-II criteria. All patients had previously
tried multiple approaches to migraine treatment without suc-
cess. Out of 60 patients, 56 had tried other standard preven-
tive therapies, and 51 had tried at least 2 different classes of
preventive therapy.
Out of 60 patients, 54 continued therapy with memantine
for at least 2 months, with ultimate doses of 5 mg, 10 mg, 15
Fig. 1 Patient experience with memantine for migraine prevention
based on completed surveys. a Average headache frequency. Left bar
indicates average estimated headache frequency for 3 months pre-
ceding memantine therapy. Right bar indicates average estimated
headache frequency for at least two months during memantine ther-
apy. Error bars indicate SEM. Memantine therapy was associated
with a significant reduction in average headache frequency (n=54,
p<10–5 using paired sample t-test). b Histogram of patient responses
to the 1–9 numerical analogue scale of “Overall number of
headaches while taking memantine as compared with before you
took it.” c Histogram of patient responses to the analogue scale of
“Overall severity of headaches while taking memantine as compared
with before you took it.” d Histogram of patient responses to the ana-
logue scale of “The overall amount of medication you took for your
headaches since you started taking memantine as compared with
before you took it.” e Histogram of patient responses to the analogue
scale of “How you felt and how well you functioned overall while
taking memantine as compared with before you took it.”
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mg and 20 mg (1, 7, 1 and 45 patients, respectively). In this
group, estimated monthly headache frequency prior to
memantine therapy ranged from 4 to 30 (median 12.5,
mean±SD 15.2±8.8). Estimated monthly headache frequen-
cy during memantine therapy ranged from 0 to 22 (median
3.5, mean 6.1±6.0) (Fig. 1). Out of 54 patients, 36 (67%)
reported a greater than 50% reduction in estimated monthly
headache frequency. The majority of patients also reported
decreased headache severity, reduced amount of medication
taken for headache and improved level of function (Fig. 1).
Out of 9 patients with daily headache, 6 reported a greater
than 50% reduction in headache. Out of 20 patients with
migraine with aura, 16 reported that it reduced the frequen-
cy of aura as well as headache. Out of 60 patients, 45 report-
ed no side effects. Reported side effects included agitation,
confusion, dizziness, weight loss, fatigue, rash and increased
headache. Six patients discontinued memantine before 1
month of therapy because of side effects [rash (1), agitation
(2), cognitive dysfunction (1), extremity pain (1)] and/or
lack of efficacy (4).
Discussion
Our results suggest that memantine can be an effective ther-
apy for prevention of migraine in patients in whom other
established migraine preventive therapies have failed.
Patients in this study had a high baseline headache frequen-
cy, and most had tried at least two standard migraine preven-
tive therapies. Even in this population, the majority of
patients had a meaningful reduction in headache frequency
and severity. Memantine was generally well tolerated,
although side effects resulted in discontinuation of the med-
ication in approximately 10% of patients.
Memantine’s pharmacological characteristics suggest that
it has the capacity to block excessive activation of NMDA
receptors without affecting normal signalling by the receptor
[4]. Memantine, like other NMDA antagonists, has been found
to modulate CSD [5]. It is therefore possible that memantine
could reduce episodic increases in cortical excitability under-
lying migraine. This potential mechanism is supported by our
observation that memantine reduced the frequency of aura as
well as headache. Memantine also blocks other ligand gated
ion channels, including nicotinic acetylcholine receptors and
5HT3 receptors [6, 7]. It could therefore have multiple other
mechanisms of action that may modulate migraine.
This study is limited by its retrospective observations,
lack of control group and lack of blinding. There are multi-
ple biases that could therefore confound these observations,
and there could be a highly significant placebo effect.
Nonetheless, the results are encouraging because of the
patient population that was studied, the overall tolerability of
the medication and the scientific rationale for a mechanism
of action in migraine prevention. Our patients’ experience
indicates that a formal prospective study of memantine’s
efficacy as a migraine preventive agent is warranted. Studies
are ongoing in our laboratory to investigate potential cellular
and pharmacological mechanisms of memantine in experi-
mental models.
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